Search Results - "Ripellino, P."

Autoreactive T cells target peripheral nerves in Guillain–Barré syndrome by Súkeníková, L., Mallone, A., Schreiner, B., Ripellino, P., Nilsson, J., Stoffel, M., Ulbrich, S. E., Sallusto, F., Latorre, D.

“…Guillain–Barré syndrome (GBS) is a rare heterogenous disorder of the peripheral nervous system, which is usually triggered by a preceding infection, and causes…”
Get full text

Variations of the perforin gene in patients with chronic inflammatory demyelinating polyradiculoneuropathy by Buttini, S, Cappellano, G, Ripellino, P, Briani, C, Cocito, D, Osio, M, Cantello, R, Dianzani, U, Comi, C

“…Perforin (PRF) has a key role in the function of cytotoxic T and natural killer cells. Rare variations of PRF1 predispose to autoimmunity. Chronic inflammatory…”
Get full text

MRI activity and neutralising antibody as predictors of response to interferon β treatment in multiple sclerosis by Durelli, L, Barbero, P, Bergui, M, Versino, E, Bassano, M A, Verdun, E, Rivoiro, C, Ferrero, C, Picco, E, Ripellino, P, Giuliani, G, Montanari, E, Clerico, M

“…Objective:To prospectively validate MRI activity and neutralising anti-interferon antibody (NAb) during the first 6 months of interferon β treatment as…”
Get full text

Clinical phenotype and outcome of hepatitis E virus associated neuralgic amyotrophy; an international retrospective comparative cohort study by Jones, K.J.E, Van Eijk, J.J.J, Ripellino, P, Madden, R.G, Herrod, J, Lissmann, R, Webb, G, Abdelrahim, M, Ashraf, H.H, Almasri, O, Mclean, B.N.P, Gobbi, C, Moradpour, D, Kuntzer, T, Benninger, D, Fraga, M, Sahli, R, Peron, J.M, Blasco-Perrin, H, Izopet, J, Colson, P, Attarian, S, Gerolami, R, Hartl, J, Pischke, S, Giordani, M.T, Fritz, M, Panning, M, Bendall, R.P, Lin, N, Van Alfen, N, Van Engelen, B, Jacobs, B.C, Dalton, H.R

Get full text

The OPTimization of Interferon for MS Study: 375 μg interferon beta-1b in suboptimal responders by Durelli, L., Barbero, P., Bergui, M., Versino, E., Bassano, M. A., Verdun, E., Ferrero, B., Rivoiro, C., Ferrero, C., Picco, E., Ripellino, P., Viglietti, D., Giuliani, G., Montanari, E., Clerico, M.

“…We aimed to evaluate the safety and MRI efficacy of interferon beta-1b (IFNβ-1b) 375 μg (subcutaneously [sc] every other day [eod]) in relapsing-remitting…”
Get full text

Progressive multifocal leucoencephalopathy after autologous bone marrow transplantation: a treatment option by Ripellino, P, Comi, C, Mula, M, Varrasi, C, Conconi, A, Stecco, A, Brustia, D, Nasuelli, N, Savio, K, De Paoli, L, Cantello, R, Gaidano, G, Monaco, F

“…A patient with multiple myeloma was treated with high-dose chemotherapy followed by two autologous bone marrow transplantations (ABMTs). Nine months after the…”
Get full text

FP17-TU-06 Th17, an effector T lymphocyte subset associated with multiple sclerosis (MS) relapses: antigen specificity, cytokine production, and sensitivity to interferon (IFN)-β by Durelli, L, Rolla, S, Conti, L, Clerico, M, Contessa, G, Ripellino, P, La Puma, D, Viglietta, E, Uccelli, A, Zaffaroni, M, Cavalla, P, Rinaldi, L, Comi, C, Novelli, F

Get full text

VP427 The Swiss cohort of LAMA2-related muscular dystrophy patients by Enzmann, C., Steiner, L., Baumann, D., Lötscher, N., Jacquier, D., Stettner, G., Henzi, B., Ripellino, P., Fluss, J., Klein, A.

“…LAMA2-related muscular dystrophy is an autosomal-recessive disorder and one of the most common forms in the group of congenital muscular dystrophies. There is…”
Get full text

1700 Clinical phenotype and outcome of hepatitis E virus associated neuralgic amyotrophy (hev-na); an international multicentre retrospective comparative study by Van Eijk, JJ, Dalton, Harry R, Ripellino, P, Madden, Richie G, Jones, C, Fritz, M, Gobbi, C, Melli, G, Pasi, E

“…BackgroundHEV-NA may have a distinct clinical phenotype and outcome compared to cases of NA without HEV infection.MethodsCases of NA were identified in 11…”
Get full text

Autoimmune liver disease serology in acute hepatitis E virus infection by Beretta-Piccoli, B. Terziroli, Ripellino, P., Gobbi, C., Cerny, A., Baserga, A., Di Bartolomeo, C., Bihl, F., Deleonardi, G., Melidona, L., Grondona, A.G., Mieli-Vergani, G., Vergani, D., Muratori, L.

Get full text

PS-104 - Clinical phenotype and outcome of hepatitis E virus associated neuralgic amyotrophy; an international retrospective comparative cohort study by Jones, K.J.E., Van Eijk, J.J.J., Ripellino, P., Madden, R.G., Herrod, J., Lissmann, R., Webb, G., Abdelrahim, M., Ashraf, H.H., Almasri, O., Mclean, B.N.P., Gobbi, C., Moradpour, D., Kuntzer, T., Benninger, D., Fraga, M., Sahli, R., Peron, J.M., Blasco-Perrin, H., Izopet, J., Colson, P., Attarian, S., Gerolami, R., Hartl, J., Pischke, S., Giordani, M.T., Fritz, M., Panning, M., Bendall, R.P., Lin, N., Van Alfen, N., Van Engelen, B., Jacobs, B.C., Dalton, H.R.

Get full text

MRI activity and neutralising antibody as predictors of response to interferon   treatment in multiple sclerosis by Durelli, L, Barbero, P, Bergui, M, Versino, E, Bassano, M A, Verdun, E, Rivoiro, C, Ferrero, C, Picco, E, Ripellino, P, Giuliani, G, Montanari, E, Clerico, M

“…Objective: To prospectively validate MRI activity and neutralising anti-interferon antibody (NAb) during the first 6 months of interferon β treatment as…”
Get full text

MRI activity and neutralising antibody as predictors of response to interferon β treatment in multiple sclerosis. Commentaries by KILLESTEIN, Joep, HARTUNG, Hans-Peter, PICCO, E, RIPELLINO, P, GIULIANI, G, MONTANARI, E, CLERICO, M, DURELLI, L, BARBERO, P, BERGUI, M, VERSINO, E, BASSANO, M. A, VERDUN, E, RIVOIRO, C, FERRERO, C

Get full text

The OPTimization of Interferon for MS Study: 375 [mu]g interferon beta-1b in suboptimal responders by Durelli, L, Barbero, P, Bergui, M, Versino, E, Bassano, M A, Verdun, E, Ferrero, B, Rivoiro, C, Ferrero, C, Picco, E, Ripellino, P, Viglietti, D, Giuliani, G, Montanari, E, Clerico, M

“…We aimed to evaluate the safety and MRI efficacy of interferon beta-1b (IFNβ-1b) 375 μg (subcutaneously [sc] every other day [eod]) in relapsing-remitting…”
Get full text

Neutralizing antibodies in multiple sclerosis patients treated with 375 micrograms interferon-beta-1b by Durelli, L, Barbero, P, Cucci, A, Ferrero, B, Ricci, A, Contessa, G, De Mercanti, S, Ripellino, P, Lapuma, D, Viglietta, E, Bergui, M, Versino, E, Clerico, M

“…Neutralizing antibodies (NAbs) to IFN-beta may have a detrimental effect on treatment response, but increasing IFN-beta dose could reduce their occurrence. The…”
Get more information

Progressive multifocal leucoencephalopathy after autologous bone marrow transplantation: a treatment option by Ripellino, P, Comi, C, Mula, M, Varrasi, C, Conconi, A, Stecco, A, Brustia, D, Nasuelli, N, Savio, K, De Paoli, L, Cantello, R, Gaidano, G, Monaco, F

“…A patient with multiple myeloma was treated with high-dose chemotherapy followed by two autologous bone marrow transplantations (ABMTs). Nine months after the…”
Get full text